ADC Therapeutics (ADCT) Cash & Equivalents (2019 - 2026)

ADC Therapeutics has disclosed Cash & Equivalents across 8 years of filings, most recently posting $231.0 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $231.0 million, up 18.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $231.0 million (up 18.65% YoY), and the FY2025 annual result was $261.3 million, up 4.17% from the prior year.
• Cash & Equivalents came in at $231.0 million for Q1 2026 at ADC Therapeutics, down from $261.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $326.4 million in Q4 2022 to a low of $194.7 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $261.3 million (2025), against an average of $259.2 million.
• Across the five-year window, Cash & Equivalents sank 30.02% in 2022 and advanced 18.65% in 2026, its largest moves.
• ADC Therapeutics' Cash & Equivalents stood at $326.4 million in 2022, then declined by 14.66% to $278.6 million in 2023, then declined by 9.95% to $250.9 million in 2024, then gained by 4.17% to $261.3 million in 2025, then slipped by 11.61% to $231.0 million in 2026.
• The last three Cash & Equivalents figures came in at $231.0 million (Q1 2026), $261.3 million (Q4 2025), and $234.7 million (Q3 2025), per Business Quant data.